Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement，make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement．


# JW（Cayman）Therapeutics Co．Ltd藥明巨諾（開曼）有限公司＊ <br> （Incorporated in the Cayman Islands with limited liability） 

（Stock Code：2126）

## RESIGNATION OF CHIEF FINANCIAL OFFICER

The board of directors（the＂Board＂）of JW（Cayman）Therapeutics Co．Ltd（the ＂Company＂，together with its subsidiaries，the（＂Group＂）），announces that Mr．Xin Fu（傅欣）（＂Mr．Fu＂）has tendered his resignation as chief financial officer of the Company（the ＂CFO＂）with effect from December 15，2023，due to his personal career development．

Mr．Fu has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited．

The Company is currently identifying a suitable candidate to fill the vacancy of the CFO and will ensure that a qualified candidate will be appointed as soon as practicable．The Company will make further announcement（s）in this regard when appropriate．

The Board would like to express its gratitude to $\mathrm{Mr} . \mathrm{Fu}$ for his efforts and valuable contributions to the Group during his tenure of office as the CFO．

By order of the Board<br>JW（Cayman）Therapeutics Co．Ltd藥明巨諾（開曼）有限公司＊<br>Yiping James Li<br>Chairman

Shanghai，PRC，December 15， 2023
As at the date of this announcement，the Board comprises Dr．Yiping James Li as Chairman and executive Director，Ms．Xing Gao，Dr．Sungwon Song and Dr．Cheng Liu as non－executive Directors，and Mr．Yiu Leung Andy Cheung，Mr．Kin Cheong Kelvin Ho，Dr．Debra Yu，Dr．Krishnan Viswanadhan and Dr．Ann Li Lee as independent non－executive Directors．
＊For identification purpose only

